MARKET

CABA

CABA

Cabaletta Bio, Inc.
NASDAQ
2.570
-0.030
-1.15%
Pre Market: 2.690 +0.12 +4.67% 04:51 02/12 EST
OPEN
2.600
PREV CLOSE
2.600
HIGH
2.610
LOW
2.475
VOLUME
518
TURNOVER
0
52 WEEK HIGH
3.670
52 WEEK LOW
0.9857
MARKET CAP
247.40M
P/E (TTM)
-1.0259
1D
5D
1M
3M
1Y
5Y
1D
Analysts Offer Insights on Healthcare Companies: Phio Pharmaceuticals (PHIO) and Cabaletta Bio (CABA)
TipRanks · 1d ago
Weekly Report: what happened at CABA last week (0202-0206)?
Weekly Report · 3d ago
Analysts Offer Insights on Healthcare Companies: Cabaletta Bio (CABA) and Ocular Therapeutix (OCUL)
TipRanks · 6d ago
Cabaletta Bio to Participate in Guggenheim Emerging Outlook Biotech Summit
Reuters · 6d ago
Cabaletta Bio participates in a conference call with William Blair
TipRanks · 02/04 15:50
12 Health Care Stocks Moving In Tuesday's After-Market Session
Benzinga · 02/03 21:05
Weekly Report: what happened at CABA last week (0126-0130)?
Weekly Report · 02/02 09:10
Cabaletta Bio: Do You Buy With The Insiders?
Seeking Alpha · 01/27 16:01
More
About CABA
Cabaletta Bio, Inc. is a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies that have the potential to provide deep and durable, perhaps curative, responses with one-time administration for patients with autoimmune diseases. Its Cabaletta Approach to B cell Ablation (CABA) platform encompasses two strategies: Chimeric Antigen Receptor T cells for Autoimmunity (CARTA) and Chimeric AutoAntibody Receptor T cells (CAART). Resecabtagene autoleucel, its lead product candidate from its CARTA platform, is a 4-1BB co-stimulatory domain-containing fully human CD19-CAR T construct designed to treat patients with a range of autoimmune diseases. Its DSG3-CAART product candidate is being evaluated for the treatment of mPV, a subtype of PV that affects the epithelium of the mucous membranes, in the Phase 1 DesCAARTes TM trial. Its MuSK-CAART product candidate is designed to treat a subset of patients with MG, targeting autoreactive B cells.

Webull offers Cabaletta Bio Inc stock information, including NASDAQ: CABA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CABA stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading CABA stock methods without spending real money on the virtual paper trading platform.